Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» weight loss
weight loss
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Yahoo/Bloomberg
Novo Nordisk
Ozempic
Wegovy
obesity
weight loss
Flag link:
Why a hidden message in Ozempic’s logo represents a big shift in drug branding
Why a hidden message in Ozempic’s logo represents a big shift in drug branding
Fast Company
Novo Nordisk
Ozempic
logo
branding
diabetes
weight loss
Flag link:
Novo Nordisk Is Already Working on Ozempic 2.0
Novo Nordisk Is Already Working on Ozempic 2.0
Motley Fool
Novo Nordisk
diabetes
obesity
weight loss
Ozempic
Wegovy
Flag link:
Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company
Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company
FT.com
Novo Nordisk
Wegovy
Europe
weight loss
Flag link:
Are weight loss drugs a win for the global economy?
Are weight loss drugs a win for the global economy?
Pharma Voice
Novo Nordisk
Wegovy
weight loss
Ozempic
Flag link:
Novo Nordisk set to launch weight loss drugs in more countries but in constrained fashion, CEO says
Novo Nordisk set to launch weight loss drugs in more countries but in constrained fashion, CEO says
Fierce Pharma
Novo Nordisk
weight loss
Wegovy
Ozempic
Flag link:
Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says
Weight-Loss Drug Wegovy Will Launch In More Countries Despite Ongoing Struggles Over Stellar Demand, CEO Says
Forbes
Novo Nordisk
Wegovy
Lars Fruergaard Jorgensen
weight loss
Flag link:
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Motley Fool
Novo Nordisk
Ozempic
diabetes
weight loss
liver disease
addiction
cardiovascular disease
Flag link:
Nearly Half Of Americans Polled Want Weight Loss Drugs But Many Lose Interest After Reading The Fine Print
Nearly Half Of Americans Polled Want Weight Loss Drugs But Many Lose Interest After Reading The Fine Print
Forbes
weight loss
Novo Nordisk
Wegovy
Ozempic
Flag link:
Demand for weight loss drugs soars to nearly half of Americans
Demand for weight loss drugs soars to nearly half of Americans
Pharma Voice
weight loss
Novo Nordisk
Ozempic
Flag link:
Report: Fewer Adults Are Interested in Weight Loss Drugs If Not Covered by Insurance
Report: Fewer Adults Are Interested in Weight Loss Drugs If Not Covered by Insurance
MedCity News
insurance
weight loss
payers
Novo Nordisk
Eli Lilly
Flag link:
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Motley Fool
Ozempic
Novo Nordisk
weight loss
diabetes
Flag link:
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
Eli Lilly
Mounjaro
obesity
weight loss
drug shortages
Flag link:
New weight loss drugs carry high price tags and lots of questions for seniors
New weight loss drugs carry high price tags and lots of questions for seniors
Medical Marketing and Media
Seniors
Wegovy
Novo Nordisk
Mounjaro
Eli Lilly
weight loss
Flag link:
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
Motley Fool
Novo Nordisk
Ozempic
obesity
diabetes
weight loss
addiction
Flag link:
More payers could stanch off-label use of Ozempic
More payers could stanch off-label use of Ozempic
Medical Marketing and Media
Novo Nordisk
Ozempic
off-label
weight loss
Flag link:
Could Pfizer Have an Ozempic Killer on the Way?
Could Pfizer Have an Ozempic Killer on the Way?
Motley Fool
Pfizer
danuglipron
Novo Nordisk
Ozempic
weight loss
Flag link:
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
obesity
weight loss
Novo Nordisk
Eli Lilly
Pfizer
Amgen
Flag link:
This Could Be Novo Nordisk's Next Big Weight-Loss Product
This Could Be Novo Nordisk's Next Big Weight-Loss Product
Motley Fool
Novo Nordisk
weight loss
Wegovy
oral Wegovy
Flag link:
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss
Investors Business Daily
Pfizer
Novo Nordisk
weight loss
Ozempic
danuglipron
clinical trials
Flag link:
Pages
1
2
3
4
5
6
7
next ›
last »